Mutation of cancer cells under the selective pressure of vaccines and the immunosuppressive tumor microenvironment limit therapeutic efficacy of cancer neoantigen vaccine. Here this group develops a nanovaccine delivering nAg and induce in situ cancer vaccination to synergistically promote a personalized immune response, enhance antigen diffusion, and improve the microenvironment by modulating immunosuppressive cells and activating the innate immune response.
- Kuanhan Feng
- Xinru Zhang
- Ruoning Wang
